Clinical Trial Update: EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the use of an EGFR tyrosine kinase inhibitor with or without whole-brain radiotherapy in patients with brain metastases f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN